Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation

Progress in Neurobiology

Volumn 88, Issue 3, 2009, Pages 170-183

  MacDonald, Jessica L ^a   Roskams, A Jane ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

DNA methyl transferase; Gene expression; Genomic instability; Histone deacetylase; Neural development; Neurodegeneration

Indexed keywords

4 PHENYLBUTYRIC ACID; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CARBOXYLIC ACID; DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPOXIDE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; TRICHOSTATIN A; VALPROIC ACID;

BIPOLAR DISORDER; BRAIN DEVELOPMENT; CHROMATIN STRUCTURE; DEACETYLATION; DNA METHYLATION; DNA MODIFICATION; ENZYME INHIBITION; EPIGENETICS; EPILEPSY; GENE EXPRESSION; GENETIC REGULATION; HUMAN; LEARNING; MALIGNANT NEOPLASTIC DISEASE; MEMORY CONSOLIDATION; MENTAL DISEASE; MIGRAINE; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STIMULUS RESPONSE; SYNAPSE; TERATOGENICITY;

ANIMALS; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HISTONES; HUMANS; NERVOUS SYSTEM;

EID: 67349204386     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.04.002     Document Type: Review

References (226)

1. Ahringer J. NuRD and SIN3 histone deacetylase complexes in development. Trends Genet. 16 (2000) 351-356
2. Alarcon J.M., Malleret G., Touzani K., Vronskaya S., Ishii S., Kandel E.R., and Barco A. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42 (2004) 947-959
3. Allan A.M., Liang X., Luo Y., Pak C., Li X., Szulwach K.E., Chen D., Jin P., and Zhao X. The loss of methyl-CpG binding protein 1 leads to autism-like behavioral deficits. Hum Mol. Genet. 17 (2008) 2047-2057
4. Amir R.E., Van den Veyver I.B., Schultz R., Malicki D.M., Tran C.Q., Dahle E.J., Philippi A., Timar L., Percy A.K., Motil K.J., Lichtarge O., Smith E.O., Glaze D.G., and Zoghbi H.Y. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann. Neurol. 47 (2000) 670-679
5. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., and Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23 (1999) 185-188
6. Anlezark G., Horton R.W., Meldrium B.S., and Sawaya C.B. Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of gamma-aminobutyric acid (GABA) in mice with audiogenic seizures. Biochem. Pharmacol. 25 (1976) 413-417
7. Armstrong D., Dunn J.K., Antalffy B., and Trivedi R. Selective dendritic alterations in the cortex of Rett syndrome. J. Neuropathol. Exp. Neurol. 54 (1995) 195-201
8. Azuara V., Perry P., Sauer S., Spivakov M., Jorgensen H.F., John R.M., Gouti M., Casanova M., Warnes G., Merkenschlager M., and Fisher A.G. Chromatin signatures of pluripotent cell lines. Nat. Cell Biol. 8 (2006) 532-538
9. Bauman M.L., Kemper T.L., and Arin D.M. Microscopic observations of the brain in Rett syndrome. Neuropediatrics 26 (1995) 105-108
10. Belichenko P.V., Hagberg B., and Dahlstrom A. Morphological study of neocortical areas in Rett syndrome. Acta Neuropathol. (Berl) 93 (1997) 50-61
11. Berger J., Sansom O., Clarke A., and Bird A. MBD2 is required for correct spatial gene expression in the gut. Mol. Cell Biol. 27 (2007) 4049-4057
12. Bernstein B.E., Kamal M., Lindblad-Toh K., Bekiranov S., Bailey D.K., Huebert D.J., McMahon S., Karlsson E.K., Kulbokas III E.J., Gingeras T.R., Schreiber S.L., and Lander E.S. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120 (2005) 169-181
13. Bernstein B.E., Meissner A., and Lander E.S. The mammalian epigenome. Cell 128 (2007) 669-681
14. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., Fry B., Meissner A., Wernig M., Plath K., Jaenisch R., Wagschal A., Feil R., Schreiber S.L., and Lander E.S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125 (2006) 315-326
15. Bienvenu T., and Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat. Rev. Genet. 7 (2006) 415-426
16. Bird A. The essentials of DNA methylation. Cell 70 (1992) 5-8
17. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16 (2002) 6-21
18. Bjerling P., Silverstein R.A., Thon G., Caudy A., Grewal S., and Ekwall K. Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol. Cell Biol. 22 (2002) 2170-2181
19. Boutillier A.L., Trinh E., and Loeffler J.P. Constitutive repression of E2F1 transcriptional activity through HDAC proteins is essential for neuronal survival. Ann. N. Y. Acad. Sci. 973 (2002) 438-442
20. Boutillier A.L., Trinh E., and Loeffler J.P. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J. Neurochem. 84 (2003) 814-828
21. Broide R.S., Redwine J.M., Aftahi N., Young W., Bloom F.E., and Winrow C.J. Distribution of histone deacetylases 1-11 in the rat brain. J. Mol. Neurosci. 31 (2007) 47-58
22. Brooks P.J., Marietta C., and Goldman D. DNA mismatch repair and DNA methylation in adult brain neurons. J. Neurosci. 16 (1996) 939-945
23. Caballero I.M., and Hendrich B. MeCP2 in neurons: closing in on the causes of Rett syndrome. Hum. Mol. Genet. 14 (2005) R19-R26 (Spec No)
24. Calof A.L., Rim P.C., Askins K.J., Mumm J.S., Gordon M.K., Iannuzzelli P., and Shou J. Factors regulating neurogenesis and programmed cell death in mouse olfactory epithelium. Ann. N. Y. Acad. Sci. 855 (1998) 226-229
25. Carney R.M., Wolpert C.M., Ravan S.A., Shahbazian M., Ashley-Koch A., Cuccaro M.L., Vance J.M., and Pericak-Vance M.A. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr. Neurol. 28 (2003) 205-211
26. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T., Qin J., and Zoghbi H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320 (2008) 1224-1229
27. Chahrour M., and Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 56 (2007) 422-437
28. Charman T., Neilson T.C., Mash V., Archer H., Gardiner M.T., Knudsen G.P., McDonnell A., Perry J., Whatley S.D., Bunyan D.J., Ravn K., Mount R.H., Hastings R.P., Hulten M., Orstavik K.H., Reilly S., Cass H., Clarke A., Kerr A.M., and Bailey M.E. Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype-phenotype associations in Rett syndrome. Eur. J. Hum. Genet. 13 (2005) 1121-1130
29. Chen R.Z., Akbarian S., Tudor M., and Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27 (2001) 327-331
30. Chwang W.B., O'Riordan K.J., Levenson J.M., and Sweatt J.D. ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning. Learn. Mem. 13 (2006) 322-328
31. Cohen D.R., Matarazzo V., Palmer A.M., Tu Y., Jeon O.H., Pevsner J., and Ronnett G.V. Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis. Mol. Cell. Neurosci. 22 (2003) 417-429
32. Colantuoni C., Jeon O.H., Hyder K., Chenchik A., Khimani A.H., Narayanan V., Hoffman E.P., Kaufmann W.E., Naidu S., and Pevsner J. Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiol. Dis. 8 (2001) 847-865
33. Covington E.C. Anticonvulsants for neuropathic pain and detoxification. Cleve. Clin. J. Med. 65 Suppl. 1 (1998) SI21-S29 (Discussion SI45-SI27)
34. Czuczwar S.J., Frey H.H., and Loscher W. Antagonism of N-methyl-d, l-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur. J. Pharmacol. 108 (1985) 273-280
35. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370 (2003) 737-749
36. Dragunow M., Greenwood J.M., Cameron R.E., Narayan P.J., O'Carroll S.J., Pearson A.G., and Gibbons H.M. Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience 140 (2006) 1149-1156
37. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463
38. Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin. Immunol. 109 (2003) 17-28
39. Emrich H.M., von Zerssen D., Kissling W., Moller H.J., and Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr. 229 (1980) 1-16
40. Endres M., Fan G., Meisel A., Dirnagl U., and Jaenisch R. Effects of cerebral ischemia in mice lacking DNA methyltransferase 1 in post-mitotic neurons. Neuroreport 12 (2001) 3763-3766
41. Endres M., Meisel A., Biniszkiewicz D., Namura S., Prass K., Ruscher K., Lipski A., Jaenisch R., Moskowitz M.A., and Dirnagl U. DNA methyltransferase contributes to delayed ischemic brain injury. J. Neurosci. 20 (2000) 3175-3181
42. Fan G., Beard C., Chen R.Z., Csankovszki G., Sun Y., Siniaia M., Biniszkiewicz D., Bates B., Lee P.P., Kuhn R., Trumpp A., Poon C., Wilson C.B., and Jaenisch R. DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J. Neurosci. 21 (2001) 788-797
43. Fan G., Martinowich K., Chin M.H., He F., Fouse S.D., Hutnick L., Hattori D., Ge W., Shen Y., Wu H., ten Hoeve J., Shuai K., and Sun Y.E. DNA methylation controls the timing of astrogliogenesis through regulation of JAK-STAT signaling. Development 132 (2005) 3345-3356
44. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., Moroni F., and Chiarugi A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70 (2006) 1876-1884
45. Farrant M., and Webster R.A. Neuronal activity, amino acid concentration and amino acid release in the substantia nigra of the rat after sodium valproate. Brain Res. 504 (1989) 49-56
46. Feng J., Chang H., Li E., and Fan G. Dynamic expression of de novo DNA methyltransferases Dnmt3a and Dnmt3b in the central nervous system. J. Neurosci. Res. 79 (2005) 734-746
47. Feng Q., and Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15 (2001) 827-832
48. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
49. Fischle W., Dequiedt F., Hendzel M.J., Guenther M.G., Lazar M.A., Voelter W., and Verdin E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9 (2002) 45-57
50. Fraga M.F., Ballestar E., Montoya G., Taysavang P., Wade P.A., and Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res. 31 (2003) 1765-1774
51. +]o in the hippocampal slice. Brain Res. 386 (1986) 1-11
52. Fujita N., Shimotake N., Ohki I., Chiba T., Saya H., Shirakawa M., and Nakao M. Mechanism of transcriptional regulation by methyl-CpG binding protein MBD1. Mol. Cell Biol. 20 (2000) 5107-5118
53. Fujita N., Takebayashi S., Okumura K., Kudo S., Chiba T., Saya H., and Nakao M. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol. Cell Biol. 19 (1999) 6415-6426
54. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 15 (2005) 490-495
55. Fuks F., Hurd P.J., Wolf D., Nan X., Bird A.P., and Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278 (2003) 4035-4040
56. Fukuda T., Itoh M., Ichikawa T., Washiyama K., and Goto Y. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J. Neuropathol. Exp. Neurol. 64 (2005) 537-544
57. Gale K. Role of the substantia nigra in GABA-mediated anticonvulsant actions. Adv. Neurol. 44 (1986) 343-364
58. Gandelman R., Zarrow M.X., Denenberg V.H., and Myers M. Olfactory bulb removal eliminates maternal behavior in the mouse. Science 171 (1971) 210-211
59. Gao L., Cueto M.A., Asselbergs F., and Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277 (2002) 25748-25755
60. Gemelli T., Berton O., Nelson E.D., Perrotti L.I., Jaenisch R., and Monteggia L.M. Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. Biol. Psychiatry 59 (2006) 468-476
61. Giacometti E., Luikenhuis S., Beard C., and Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc. Natl. Acad. Sci. USA 104 (2007) 1931-1936
62. Godin Y., Heiner L., Mark J., and Mandel P. Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism. J. Neurochem. 16 (1969) 869-873
63. Goldberg A.D., Allis C.D., and Bernstein E. Epigenetics: a landscape takes shape. Cell 128 (2007) 635-638
64. Goll M.G., and Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 74 (2005) 481-514
65. Goto K., Numata M., Komura J.I., Ono T., Bestor T.H., and Kondo H. Expression of DNA methyltransferase gene in mature and immature neurons as well as proliferating cells in mice. Differentiation 56 (1994) 39-44
66. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
67. Grayson D.R., Jia X., Chen Y., Sharma R.P., Mitchell C.P., Guidotti A., and Costa E. Reelin promoter hypermethylation in schizophrenia. Proc. Natl. Acad. Sci. USA 102 (2005) 9341-9346
68. Gregoretti I.V., Lee Y.M., and Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338 (2004) 17-31
69. Grozinger C.M., Chao E.D., Blackwell H.E., Moazed D., and Schreiber S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276 (2001) 38837-38843
70. Guan Z., Giustetto M., Lomvardas S., Kim J.H., Miniaci M.C., Schwartz J.H., Thanos D., and Kandel E.R. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 111 (2002) 483-493
71. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96 (2002) 45-66
72. Guy J., Gan J., Selfridge J., Cobb S., and Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315 (2007) 1143-1147
73. Guy J., Hendrich B., Holmes M., Martin J.E., and Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27 (2001) 322-326
74. Hagberg B. Rett's syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr. Scand. 74 (1985) 405-408
75. Hagberg B., Aicardi J., Dias K., and Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann. Neurol. 14 (1983) 471-479
76. Hammer S., Dorrani N., Hartiala J., Stein S., and Schanen N.C. Rett syndrome in a 47, XXX patient with a de novo MECP2 mutation. Am. J. Med. Genet. A 122 (2003) 223-226
77. Hansen R.S., Wijmenga C., Luo P., Stanek A.M., Canfield T.K., Weemaes C.M., and Gartler S.M. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc. Natl. Acad. Sci. USA 96 (1999) 14412-14417
78. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., Gould T.D., Manji H.K., and Chen G. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24 (2004) 6590-6599
79. Hariton C., Ciesielski L., Simler S., Valli M., Jadot G., Gobaille S., Mesdjian E., and Mandel P. Distribution of sodium valproate and GABA metabolism in CNS of the rat. Biopharm. Drug Dispos. 5 (1984) 409-414
80. Hark A.T., Schoenherr C.J., Katz D.J., Ingram R.S., Levorse J.M., and Tilghman S.M. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405 (2000) 486-489
81. Hendrich B., and Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell Biol. 18 (1998) 6538-6547
82. Hendrich B., Guy J., Ramsahoye B., Wilson V.A., and Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 15 (2001) 710-723
83. Hendrich B., Hardeland U., Ng H.H., Jiricny J., and Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401 (1999) 301-304
84. Hendrich B., and Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet. 19 (2003) 269-277
85. Hsieh J., and Gage F.H. Chromatin remodeling in neural development and plasticity. Curr. Opin. Cell Biol. 17 (2005) 664-671
86. Hsieh J., Nakashima K., Kuwabara T., Mejia E., and Gage F.H. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl. Acad. Sci. USA 101 (2004) 16659-16664
87. Huang Y., Doherty J.J., and Dingledine R. Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J. Neurosci. 22 (2002) 8422-8428
88. Hutchins A.S., Mullen A.C., Lee H.W., Sykes K.J., High F.A., Hendrich B.D., Bird A.P., and Reiner S.L. Gene silencing quantitatively controls the function of a developmental trans-activator. Mol. Cell 10 (2002) 81-91
89. Inano K., Suetake I., Ueda T., Miyake Y., Nakamura M., Okada M., and Tajima S. Maintenance-type DNA methyltransferase is highly expressed in post-mitotic neurons and localized in the cytoplasmic compartment. J. Biochem. (Tokyo) 128 (2000) 315-321
90. Jaenisch R., and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33 Suppl. (2003) 245-254
91. Jellinger K., Armstrong D., Zoghbi H.Y., and Percy A.K. Neuropathology of Rett syndrome. Acta Neuropathol. (Berl) 76 (1988) 142-158
92. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
93. Jessberger S., Nakashima K., Clemenson Jr. G.D., Mejia E., Mathews E., Ure K., Ogawa S., Sinton C.M., Gage F.H., and Hsieh J. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. J. Neurosci. 27 (2007) 5967-5975
94. Jian L., Archer H.L., Ravine D., Kerr A., de Klerk N., Christodoulou J., Bailey M.E., Laurvick C., and Leonard H. p.R270X MECP2 mutation and mortality in Rett syndrome. Eur. J. Hum. Genet. 13 (2005) 1235-1238
95. Jin B., Tao Q., Peng J., Soo H.M., Wu W., Ying J., Fields C.R., Delmas A.L., Liu X., Qiu J., and Robertson K.D. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum. Mol. Genet. 17 (2008) 690-709
96. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem. Int. 37 (2000) 103-110
97. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
98. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., and Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19 (1998) 187-191
99. Jorgensen H.F., Ben-Porath I., and Bird A.P. Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol. Cell Biol. 24 (2004) 3387-3395
100. Jung B.P., Jugloff D.G., Zhang G., Logan R., Brown S., and Eubanks J.H. The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells. J. Neurobiol. 55 (2003) 86-96
101. Jung B.P., Zhang G., Ho W., Francis J., and Eubanks J.H. Transient forebrain ischemia alters the mRNA expression of methyl DNA-binding factors in the adult rat hippocampus. Neuroscience 115 (2002) 515-524
102. Jung B.P., Zhang G., Nitsch R., Trogadis J., Nag S., and Eubanks J.H. Differential expression of methyl CpG-binding domain containing factor MBD3 in the developing and adult rat brain. J. Neurobiol. 55 (2003) 220-232
103. Kaji K., Caballero I.M., MacLeod R., Nichols J., Wilson V.A., and Hendrich B. The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat. Cell Biol. 8 (2006) 285-292
104. Khochbin S., and Wolffe A.P. The origin and utility of histone deacetylases. FEBS Lett. 419 (1997) 157-160
105. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., and Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007) 892-901
106. Kishi N., and Macklis J.D. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol. Cell Neurosci. 27 (2004) 306-321
107. Klose R.J., Sarraf S.A., Schmiedeberg L., McDermott S.M., Stancheva I., and Bird A.P. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol. Cell 19 (2005) 667-678
108. Knoepfler P.S., and Eisenman R.N. Sin meets NuRD and other tails of repression. Cell 99 (1999) 447-450
109. Korzus E., Rosenfeld M.G., and Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42 (2004) 961-972
110. Kouzarides T. Chromatin modifications and their function. Cell 128 (2007) 693-705
111. Kramer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., Brill B., Groner B., Bach I., Heinzel T., and Gottlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22 (2003) 3411-3420
112. Kukino K., and Deguchi T. Anticonvulsant activity and effects of sodium dipropylacetate on cerebral 5-hydroxytryptamine and gamma-aminobutyric acid in reserpinized mice. Chem. Pharm. Bull. (Tokyo) 26 (1978) 3551-3555
113. Kumar A., Choi K.H., Renthal W., Tsankova N.M., Theobald D.E., Truong H.T., Russo S.J., Laplant Q., Sasaki T.S., Whistler K.N., Neve R.L., Self D.W., and Nestler E.J. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 48 (2005) 303-314
114. Ladd-Acosta C., Pevsner J., Sabunciyan S., Yolken R.H., Webster M.J., Dinkins T., Callinan P.A., Fan J.B., Potash J.B., and Feinberg A.P. DNA methylation signatures within the human brain. Am. J. Hum. Genet. 81 (2007) 1304-1315
115. Laeng P., Pitts R.L., Lemire A.L., Drabik C.E., Weiner A., Tang H., Thyagarajan R., Mallon B.S., and Altar C.A. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J. Neurochem. 91 (2004) 238-251
116. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T., and Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21 (2002) 2672-2681
117. Lampen A., Siehler S., Ellerbeck U., Gottlicher M., and Nau H. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol. Appl. Pharmacol. 160 (1999) 238-249
118. Langley B., D'Annibale M.A., Suh K., Ayoub I., Tolhurst A., Bastan B., Yang L., Ko B., Fisher M., Cho S., Beal M.F., and Ratan R.R. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci. 28 (2008) 163-176
119. Langley B., Gensert J.M., Beal M.F., and Ratan R.R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 41-50
120. Larsson O.M., Gram L., Schousboe I., and Schousboe A. Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes. Neuropharmacology 25 (1986) 617-625
121. Lea M.A., and Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res. 15 (1995) 879-883
122. Leonard H., and Bower C. Is the girl with Rett syndrome normal at birth?. Dev. Med. Child. Neurol. 40 (1998) 115-121
123. Levenson J.M., O'Riordan K.J., Brown K.D., Trinh M.A., Molfese D.L., and Sweatt J.D. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279 (2004) 40545-40559
124. Levenson J.M., Roth T.L., Lubin F.D., Miller C.A., Huang I.C., Desai P., Malone L.M., and Sweatt J.D. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J. Biol. Chem. 281 (2006) 15763-15773
125. Lewis J.D., Meehan R.R., Henzel W.J., Maurer-Fogy I., Jeppesen P., Klein F., and Bird A. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69 (1992) 905-914
126. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
127. Liu A., Han Y.R., Li J., Sun D., Ouyang M., Plummer M.R., and Casaccia-Bonnefil P. The glial or neuronal fate choice of oligodendrocyte progenitors is modulated by their ability to acquire an epigenetic memory. J. Neurosci. 27 (2007) 7339-7343
128. Liu H., Hu Q., Kaufman A., D'Ercole A.J., and Ye P. Developmental expression of histone deacetylase 11 in the murine brain. J. Neurosci. Res. 86 (2008) 537-543
129. Loscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 501 (1989) 198-203
130. Loscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem. Res. 18 (1993) 485-502
131. Luger K., Mader A.W., Richmond R.K., Sargent D.F., and Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389 (1997) 251-260
132. Luikenhuis S., Giacometti E., Beard C.F., and Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl. Acad. Sci. USA 101 (2004) 6033-6038
133. Lunyak V.V., Burgess R., Prefontaine G.G., Nelson C., Sze S.H., Chenoweth J., Schwartz P., Pevzner P.A., Glass C., Mandel G., and Rosenfeld M.G. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298 (2002) 1747-1752
134. Lunyak V.V., Prefontaine G.G., and Rosenfeld M.G. REST and peace for the neuronal-specific transcriptional program. Ann. N. Y. Acad. Sci. 1014 (2004) 110-120
135. Lyssiotis C.A., Walker J., Wu C., Kondo T., Schultz P.G., and Wu X. Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc. Natl. Acad. Sci. USA 104 (2007) 14982-14987
136. MacDonald J.L., Gin C.S., and Roskams A.J. Stage-specific induction of DNA methyltransferases in olfactory receptor neuron development. Dev. Biol. 288 (2005) 461-473
137. MacDonald J.L., and Roskams A.J. Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Dev. Dyn. 237 (2008) 2256-2267
138. MacDonald, J.L., Berndt, A., Verster, A., Roskams, A.J., manuscript in review. MBD2 and MeCP2 regulate distinct transitions in the stage-specific differentiation of olfactory receptor neurons.
139. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
140. Matarazzo V., Cohen D., Palmer A.M., Simpson P.J., Khokhar B., Pan S.J., and Ronnett G.V. The transcriptional repressor Mecp2 regulates terminal neuronal differentiation. Mol. Cell Neurosci. 27 (2004) 44-58
141. McLean M.J., and Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237 (1986) 1001-1011
142. Meehan R.R., Lewis J.D., McKay S., Kleiner E.L., and Bird A.P. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58 (1989) 499-507
143. Meloni I., Bruttini M., Longo I., Mari F., Rizzolio F., D'Adamo P., Denvriendt K., Fryns J.P., Toniolo D., and Renieri A. A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am. J. Hum. Genet. 67 (2000) 982-985
144. Meunier H., Carraz G., Neunier Y., Eymard P., and Aimard M. Pharmacodynamic properties of N-dipropylacetic acid. Therapie 18 (1963) 435-438
145. Miller C.A., and Sweatt J.D. Covalent modification of DNA regulates memory formation. Neuron 53 (2007) 857-869
146. Miltenberger-Miltenyi G., and Laccone F. Mutations and polymorphisms in the human methyl CpG-binding protein MECP2. Hum. Mutat. 22 (2003) 107-115
147. Morrison B.E., Majdzadeh N., and D'Mello S.R. Histone deacetylases: focus on the nervous system. Cell. Mol. Life Sci. 64 (2007) 2258-2269
148. Morrison B.E., Majdzadeh N., Zhang X., Lyles A., Bassel-Duby R., Olson E.N., and D'Mello S.R. Neuroprotection by histone deacetylase-related protein. Mol. Cell Biol. 26 (2006) 3550-3564
149. Mullaney B.C., Johnston M.V., and Blue M.E. Developmental expression of methyl-CpG binding protein 2 is dynamically regulated in the rodent brain. Neuroscience 123 (2004) 939-949
150. Mumm J.S., Shou J., and Calof A.L. Colony-forming progenitors from mouse olfactory epithelium: evidence for feedback regulation of neuron production. Proc. Natl. Acad. Sci. USA 93 (1996) 11167-11172
151. Nan X., Campoy F.J., and Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88 (1997) 471-481
152. Nan X., Cross S., and Bird A. Gene silencing by methyl-CpG-binding proteins. Novartis Found. Symp. 214 (1998) 6-16 (Discussion 16-21, 46-50)
153. Nan X., Meehan R.R., and Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 21 (1993) 4886-4892
154. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., and Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393 (1998) 386-389
155. Nan X., Tate P., Li E., and Bird A. DNA methylation specifies chromosomal localization of MeCP2. Mol. Cell Biol. 16 (1996) 414-421
156. Nau H., Hauck R.S., and Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69 (1991) 310-321
157. Ng H.H., Jeppesen P., and Bird A. Active repression of methylated genes by the chromosomal protein MBD1. Mol. Cell Biol. 20 (2000) 1394-1406
158. Ng H.H., Zhang Y., Hendrich B., Johnson C.A., Turner B.M., Erdjument-Bromage H., Tempst P., Reinberg D., and Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23 (1999) 58-61
159. Nguyen S., Meletis K., Fu D., Jhaveri S., and Jaenisch R. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. Dev. Dyn. 236 (2007) 1663-1676
160. Okano M., Bell D.W., Haber D.A., and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999) 247-257
161. Orrico A., Lam C., Galli L., Dotti M.T., Hayek G., Tong S.F., Poon P.M., Zappella M., Federico A., and Sorrentino V. MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett. 481 (2000) 285-288
162. Paulsen M., and Ferguson-Smith A.C. DNA methylation in genomic imprinting, development, and disease. J. Pathol. 195 (2001) 97-110
163. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
164. Pradhan S., Bacolla A., Wells R.D., and Roberts R.J. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J. Biol. Chem. 274 (1999) 33002-33010
165. Prokhortchouk A., Hendrich B., Jorgensen H., Ruzov A., Wilm M., Georgiev G., Bird A., and Prokhortchouk E. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev. 15 (2001) 1613-1618
166. Prozorovski T., Schulze-Topphoff U., Glumm R., Baumgart J., Schroter F., Ninnemann O., Siegert E., Bendix I., Brustle O., Nitsch R., Zipp F., and Aktas O. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat. Cell Biol. 10 (2008) 385-394
167. Ramsahoye B.H., Biniszkiewicz D., Lyko F., Clark V., Bird A.P., and Jaenisch R. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. Natl. Acad. Sci. USA 97 (2000) 5237-5242
168. Ren M., Leng Y., Jeong M., Leeds P.R., and Chuang D.M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89 (2004) 1358-1367
169. Rett A. On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien. Med. Wochenschr. 116 (1966) 723-726
170. Robert E., and Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 2 (1982) 937
171. Roopra A., Qazi R., Schoenike B., Daley T.J., and Morrison J.F. Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol. Cell 14 (2004) 727-738
172. Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P., and Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22 (2003) 6537-6549
173. Russo V.E.A., Martienssen R.A., and Riggs A.D. Epigenetic Mechanisms of Gene Regulation (1996), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
174. Saha R.N., and Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell. Death Differ. 13 (2006) 539-550
175. Saito M., and Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J. Biol. Chem. 277 (2002) 35434-35439
176. Salminen A., Tapiola T., Korhonen P., and Suuronen T. Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res. Mol. Brain Res. 61 (1998) 203-206
177. Sansom O.J., Berger J., Bishop S.M., Hendrich B., Bird A., and Clarke A.R. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat. Genet. 34 (2003) 145-147
178. Schanen C., Houwink E.J., Dorrani N., Lane J., Everett R., Feng A., Cantor R.M., and Percy A. Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome. Am. J. Med. Genet. A 126 (2004) 129-140
179. Sealy L., and Chalkley R. The effect of sodium butyrate on histone modification. Cell 14 (1978) 115-121
180. Shahbazian M., Young J., Yuva-Paylor L., Spencer C., Antalffy B., Noebels J., Armstrong D., Paylor R., and Zoghbi H. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35 (2002) 243-254
181. Shahbazian M.D., Antalffy B., Armstrong D.L., and Zoghbi H.Y. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 11 (2002) 115-124
182. Shahbazian M.D., and Zoghbi H.Y. Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr. Opin. Neurol. 14 (2001) 171-176
183. Shen S., Li J., and Casaccia-Bonnefil P. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. J. Cell Biol. 169 (2005) 577-589
184. Siebzehnrubl F.A., Buslei R., Eyupoglu I.Y., Seufert S., Hahnen E., and Blumcke I. Histone deacetylase inhibitors increase neuronal differentiation in adult forebrain precursor cells. Exp. Brain Res. 176 (2007) 672-678
185. Siegmund K.D., Connor C.M., Campan M., Long T.I., Weisenberger D.J., Biniszkiewicz D., Jaenisch R., Laird P.W., and Akbarian S. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS ONE 2 (2007) e895
186. Silberstein S.D. Divalproex sodium in headache: literature review and clinical guidelines. Headache 36 (1996) 547-555
187. Slater G.E., and Johnston D. Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia 19 (1978) 379-384
188. Smrt R.D., Eaves-Egenes J., Barkho B.Z., Santistevan N.J., Zhao C., Aimone J.B., Gage F.H., and Zhao X. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol. Dis. 27 (2007) 77-89
189. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
190. Swank M.W., and Sweatt J.D. Increased histone acetyltransferase and lysine acetyltransferase activity and biphasic activation of the ERK/RSK cascade in insular cortex during novel taste learning. J. Neurosci. 21 (2001) 3383-3391
191. Takizawa T., Nakashima K., Namihira M., Ochiai W., Uemura A., Yanagisawa M., Fujita N., Nakao M., and Taga T. DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Dev. Cell 1 (2001) 749-758
192. Teter B., Rozovsky I., Krohn K., Anderson C., Osterburg H., and Finch C. Methylation of the glial fibrillary acidic protein gene shows novel biphasic changes during brain development. Glia 17 (1996) 195-205
193. Traynor J., Agarwal P., Lazzeroni L., and Francke U. Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med. Genet. 3 (2002) 12
194. Tudor M., Akbarian S., Chen R.Z., and Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc. Natl. Acad. Sci. USA 99 (2002) 15536-15541
195. Tunnicliff G. Actions of sodium valproate on the central nervous system. J. Physiol. Pharmacol. 50 (1999) 347-365
196. Ueda Y., Okano M., Williams C., Chen T., Georgopoulos K., and Li E. Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. Development 133 (2006) 1183-1192
197. Vakoc C.R., Mandat S.A., Olenchock B.A., and Blobel G.A. Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin. Mol. Cell 19 (2005) 381-391
198. Van den Berg R.J., Kok P., and Voskuyl R.A. Valproate and sodium currents in cultured hippocampal neurons. Exp. Brain Res. 93 (1993) 279-287
199. van der Laan J.W., de Boer T., and Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J. Neurochem. 32 (1979) 1769-1780
200. Van Esch H., Bauters M., Ignatius J., Jansen M., Raynaud M., Hollanders K., Lugtenberg D., Bienvenu T., Jensen L.R., Gecz J., Moraine C., Marynen P., Fryns J.P., and Froyen G. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 77 (2005) 442-453
201. Veldic M., Caruncho H.J., Liu W.S., Davis J., Satta R., Grayson D.R., Guidotti A., and Costa E. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc. Natl. Acad. Sci. USA 101 (2004) 348-353
202. Veldic M., Guidotti A., Maloku E., Davis J.M., and Costa E. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc. Natl. Acad. Sci. USA 102 (2005) 2152-2157
203. Vignali M., Hassan A.H., Neely K.E., and Workman J.L. ATP-dependent chromatin-remodeling complexes. Mol. Cell Biol. 20 (2000) 1899-1910
204. Villar-Garea A., and Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 112 (2004) 171-178
205. Waddington C. The epigenotype. Endeavour 1 (1942) 18-20
206. Wade P.A. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. 10 (2001) 693-698
207. Wade P.A., Gegonne A., Jones P.L., Ballestar E., Aubry F., and Wolffe A.P. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23 (1999) 62-66
208. Watson P., Black G., Ramsden S., Barrow M., Super M., Kerr B., and Clayton-Smith J. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J. Med. Genet. 38 (2001) 224-228
209. Whittle S.R., and Turner A.J. Effects of the anticonvulsant sodium valproate on gamma-aminobutyrate and aldehyde metabolism in ox brain. J. Neurochem. 31 (1978) 1453-1459
210. Wijmenga C., Hansen R.S., Gimelli G., Bjorck E.J., Davies E.G., Valentine D., Belohradsky B.H., van Dongen J.J., Smeets D.F., van den Heuvel L.P., Luyten J.A., Strengman E., Weemaes C., and Pearson P.L. Genetic variation in ICF syndrome: evidence for genetic heterogeneity. Hum. Mutat. 16 (2000) 509-517
211. Wikinski S.I., Acosta G.B., and Rubio M.C. Valproic acid differs in its in vitro effect on glutamic acid decarboxylase activity in neonatal and adult rat brain. Gen. Pharmacol. 27 (1996) 635-638
212. Willard H.F., and Hendrich B.D. Breaking the silence in Rett syndrome. Nat. Genet. 23 (1999) 127-128
213. Wood M.A., Kaplan M.P., Park A., Blanchard E.J., Oliveira A.M., Lombardi T.L., and Abel T. Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn. Mem. 12 (2005) 111-119
214. Xu G.L., Bestor T.H., Bourc'his D., Hsieh C.L., Tommerup N., Bugge M., Hulten M., Qu X., Russo J.J., and Viegas-Pequignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402 (1999) 187-191
215. Yamaguchi M., Tonou-Fujimori N., Komori A., Maeda R., Nojima Y., Li H., Okamoto H., and Masai I. Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt and Notch signaling pathways. Development 132 (2005) 3027-3043
216. Yamamoto R., Yanagita T., Kobayashi H., Yokoo H., and Wada A. Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. J. Neurochem. 68 (1997) 1655-1662
217. Yang X.J., and Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9 (2008) 206-218
218. Yasui D.H., Peddada S., Bieda M.C., Vallero R.O., Hogart A., Nagarajan R.P., Thatcher K.N., Farnham P.J., and Lasalle J.M. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl. Acad. Sci. USA 104 (2007) 19416-19421
219. Yoder J.A., Soman N.S., Verdine G.L., and Bestor T.H. DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe. J. Mol. Biol. 270 (1997) 385-395
220. Yoon H.G., Chan D.W., Reynolds A.B., Qin J., and Wong J. N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol. Cell 12 (2003) 723-734
221. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265 (1990) 17174-17179
222. Young J.I., Hong E.P., Castle J.C., Crespo-Barreto J., Bowman A.B., Rose M.F., Kang D., Richman R., Johnson J.M., Berget S., and Zoghbi H.Y. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. USA 102 (2005) 17551-17558
223. Zeise M.L., Kasparow S., and Zieglgansberger W. Valproate suppresses N-methyl-d-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 544 (1991) 345-348
224. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., and Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13 (1999) 1924-1935
225. Zhao X., Ueba T., Christie B.R., Barkho B., McConnell M.J., Nakashima K., Lein E.S., Eadie B.D., Willhoite A.R., Muotri A.R., Summers R.G., Chun J., Lee K.F., and Gage F.H. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc. Natl. Acad. Sci. USA 100 (2003) 6777-6782
226. Zimmermann S., Kiefer F., Prudenziati M., Spiller C., Hansen J., Floss T., Wurst W., Minucci S., and Gottlicher M. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 67 (2007) 9047-9054